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1015-9584/Copyright ª 2014, Asian SuSummary Background: The number of antihypertensive drug classes cannot accurately
reflect the total consumption of antihypertensive drugs used to control blood pressure. The
defined daily dose has been adopted to permit consumption analysis of many prescribed drugs.
The aim of the present study was to assess postoperative changes in antihypertensive drug con-
sumption in patients with primary aldosteronism using the defined daily dose as the unit of
measurement.
Methods: This retrospective study included 110 Japanese patients who underwent unilateral
laparoscopic adrenalectomy between 1995 and 2012. Antihypertensive drug doses were calcu-
lated according to the standard of the defined daily dose recommended by the World Health
Organization to compare drug use. After assessing postoperative changes in antihypertensive
drug consumption, univariate and multivariate analyses were performed to identify clinical
predictors for a 75% or greater decrease in the defined daily dose.
Results: Consumption of antihypertensive drugs decreased postoperatively in 95.4% of pa-
tients. The median decrease in the defined daily dose was 76.8%. A postoperative decreaseeclare that they have no financial or non-financial conflicts of interest related to the subject matter
ipt.
of Urology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba
.ne.jp (T. Utsumi).
14.01.011
rgical Association. Published by Elsevier Taiwan LLC. All rights reserved.
Assessment of antihypertensive drug consumption 191of 75% or greater in the defined daily dose was confirmed in 52.7% of patients. Multivariate
analysis identified no medical history of cardiovascular disease, low body mass index, and short
duration of hypertension as independent predictors of a postoperative decrease of 75% or
greater in the defined daily dose.
Conclusion: The defined daily dose is a useful tool for assessing total changes in the consump-
tion of antihypertensive drugs in patients with primary aldosteronism. Using the defined daily
dose, clinicians could explain in detail to patients with primary aldosteronism the predicted
postoperative change in antihypertensive drug consumption.
Copyright ª 2014, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Primary aldosteronism (PA) is caused by the autonomous
secretion of aldosterone from adrenocortical lesions, and it
is associated with hypertension due to sodium retention
and hypokalemia due to increased potassium excretion.1e3
Aldosterone excess leads to cardiovascular damage, inde-
pendent of its effects on blood pressure (BP).1e3 Primary
aldosteronism is primarily caused by an aldosterone-
producing adenoma (APA) or by bilateral adrenal hyper-
plasia (also known as idiopathic hyperaldosteronism).1e3
Laparoscopic adrenalectomy is the preferred approach
to treat patients with unilateral PA such as APA.4e6 Despite
normalization of the endocrine abnormalities, not all pa-
tients with PA have their hypertension cured completely by
laparoscopic adrenalectomy.1e3 Many predictors of hyper-
tension cure in PA patients have been reported.7 The
number of antihypertensive drug classes can be a robust
predictor for postoperative hypertension cure in PA
patients.7e11 However, it cannot reflect the total con-
sumption of antihypertensive drugs to control BP
accurately.
Using the number of antihypertensive drug classes as a
unit of measurement, the following two types of patients
can be regarded as taking an equivalent amount of anti-
hypertensive drugs: (1) patients who take 50 mg of epler-
enone and 5 mg of amlodipine and (2) patients who take
100 mg of eplerenone and 10 mg of amlodipine. However,
the second type of patient apparently has more severe
hypertension, despite taking the equivalent two classes of
antihypertensive drugs.
The defined daily dose (DDD) has been adopted to assess
the consumption of many prescribed drugs.12,13 The doses
of diverse drugs were calculated in accordance with the
standard of the DDD recommended by the World Health
Organization (WHO) to compare drug use.14 At present,
clinicians can search each drug’s DDD at the web address
http://www.whocc.no/atc_ddd_index. The DDD system is
often applied at the population level; however, in many
studies, it can be used to compare individual drug utiliza-
tion as a unit of measurement.12e18
The aim of this study was to assess postoperative
changes in antihypertensive drug consumption in PA pa-
tients, using the DDD as the measurement unit, and to
identify clinical predictors for decreased antihypertensive
drug consumption.2. Methods
2.1. Patient selection
The clinical variables associated with a postoperative
decrease in antihypertensive drug consumption were sur-
veyed retrospectively among PA patients seen at the Chiba
University Hospital Chiba, Japan. One hundred and ten
patients with PA who underwent unilateral laparoscopic
adrenalectomy between 1995 and 2012 were analyzed. The
criteria used to establish the diagnosis of PA were a history
of hypertension resistant to antihypertensive drugs with or
without hypokalemia, and increased plasma aldosterone
concentration (PAC) and suppressed plasma renin activity
(PRA). In this study, patients had a confirmed PAC:PRA ratio
of at least 20.0 ng/dL per ng/mL/hour as a biochemical
screen for PA.1e3 Additional confirmation of the diagnosis
was obtained using the saline-loading test, the captopril-
challenge test, and/or the upright furosemide-loading
test.1e3 Differentiation between APA and idiopathic
hyperaldosteronism was obtained by computed tomography
or by magnetic resonance imaging. Furthermore, laterali-
zation of aldosterone overproduction was demonstrated
through adrenal vein sampling (AVS) and/or adrenal
dexamethasone-suppression scintigraphy with 131iodine
(131I) cholesterol in all patients.1e3,5 The result of AVS was
used to identify unilateral hypersecretion. When the finding
of scintigraphy was equivocal or contrary to that of AVS, the
AVS results were given precedence over the results of
scintigraphy.
Postoperative normalization of plasma aldosterone
levels was defined as decreased concentration of plasma
aldosterone (<15.0 ng/dL). In this study, all patients were
confirmed to have normalized plasma aldosterone levels
after laparoscopic adrenalectomy. Hypokalemia cure was
achieved after surgery in all patients with preoperative
hypokalemia. The underlying adrenocortical lesion was
pathologically identified in all patients after surgery.
Pathological findings revealed cortical adenoma in 95 pa-
tients and nodular hyperplasia in 15 patients.
2.2. Definitions
The BP of each patient was classified in accordance with
WHO 1999 guidelines as normal BP (<140/90 mmHg) or
192 T. Utsumi et al.hypertension.19 Clinicians prescribed antihypertensive
drugs to the patients to maintain a normal BP when the
patients were hypertensive without antihypertensive drugs
after surgery.
The DDD is the assumed average maintenance dose per
day for a drug used for its main indication in adults.14 The
DDD provides a fixed unit of measurement, independent of
price and dosage form, thereby enabling researchers to
assess and compare drug consumption.14 Using the DDD,
consumption of antihypertensive drugs in PA patients was
assessed preoperatively and at 6 months postoperatively.14
Table 1 shows an example of calculating individual DDDs of
antihypertensive drugs. A change in the DDD was defined as
follows: change in the DDD% Z (preoperative total DDD e
postoperative total DDD)/preoperative total DDD  100.
Using the example in Table 1, the decrease in the DDD was
consequently 75.0%.
2.3. Data collection
The following were collected from the patients’ medical
records: age, sex, body mass index (BMI), family history of
hypertension in first-degree relatives, comorbidities,
duration of hypertension, the DDD of antihypertensive
drugs, the systolic BP and diastolic BP, and clinical labora-
tory data. Comorbidities included cardiovascular disease,
diabetes mellitus, and subclinical Cushing syndrome. The
laboratory data included serum potassium, PAC, PRA, and
estimated glomerular filtration rate (eGFR). We calculated
the eGFR using a new equation that has been developed
and validated in a Japanese population.20
2.4. Statistical analysis
The results are reported as the median (range) or as the
mean  the standard deviation, as appropriate. First, each
patient’s DDD was calculated, and the change was
compared using the Wilcoxon signed rank test. Second, the
patients were divided into two groups, according to
whether a decrease in the DDD was 75% or greater at the 6-
month follow-up assessment. The cutoff value of 75% was
based on the median change in the DDD. Third, univariateTable 1 Calculation example for the individual defined
daily dose.
Preop daily
consumption
(mg/day)
DDD (mg/day) DDD
Eplerenone 100 50 100/50 Z 2.0
Amlodipine 10 5 10/5 Z 2.0
Total DDD 4.0
Postop daily
consumption
(mg/day)
DDD (mg/day) DDD
Cilnidipine 10 10 10/10 Z 1.0
Total DDD 1.0
DDD Z defined daily dose; Postop Z postoperative;
Preop Z preoperative.analyses were performed to estimate the association be-
tween a postoperative decrease of 75% or greater in the
DDD and the preoperative variables. Continuous parametric
variables were compared using t tests. Nonparametric
variables were compared using Mann-Whitney U tests.
Categorical variables were compared using c2 tests or
Fisher’s exact test. After significant candidate variables
were selected on the basis of univariate analyses, multi-
variate logistic regression analysis was used to identify
clinical predictors associated with a postoperative decrease
of 75% or greater in the DDD. Statistical significance was
defined as p < 0.05. All statistical analyses were performed
using SAS version 9.2 software (SAS Institute, Cary, NC,
USA).
3. Results
Table 2 shows the DDDs of each antihypertensive drug class
used before and after surgery and the number of patients
who took each antihypertensive drug class. No patient in
this study took combination products such as an angiotensin
receptor blocker with diuretics. In this study, the DDDs
decreased significantly from 2.4  1.2 preoperatively to
1.0  1.2 postoperatively (p < 0.01). At the 6-month follow
up, the DDD decreased in 101 patients. By contrast, the
DDD increased in five patients and did not change in four
patients.
The median change in the DDD was e76.8%. The pro-
portion of patients with a postoperative decrease of 75% or
greater in the DDD was 52.7%. Table 3 shows the predictors
associated with a postoperative decrease of 75% or greater
in the DDD on univariate analyses. The following variables
were significantly associated with a postoperative decrease
in the DDD of 75% or greater: age, sex, BMI, medical history
of cardiovascular disease, duration of hypertension, pre-
operative DDD of antihypertensive drugs, preoperative
systolic BP, PRA, and eGFR (p < 0.05). These significant
variables were examined by multivariate logistic regression
analysis, which identified no medical history of cardiovas-
cular disease [odds ratio (OR) 5.44, pZ 0.02], low BMI (ORTable 2 Defined daily doses of each antihypertensive drug
class the patients used before and after surgery.
Antihypertensive drug class Preop DDD Postop DDD
Aldosterone antagonist 1.0  0.5 1.1  0.7
N 106 4
Calcium channel blocker 1.3  0.5 1.2  0.6
N 98 61
a-blocker 0.6  0.3 0.6  0.2
N 19 8
Angiotensin receptor blocker 1.2  0.5 1.1  0.4
N 15 15
b-blocker 0.5  0.4 0.3  0.2
N 6 5
Other antihypertensive drugs 0.9  0.4 1.1  0.1
N 5 4
Data are presented as mean  SD, unless otherwise indicated.
DDD Z defined daily dose; N Z number of patients;
Postop Z postoperative; Preop Z preoperative.
Table 4 Multivariate logistic regression analysis of sig-
nificant candidate predictors for a postoperative decrease
Assessment of antihypertensive drug consumption 1931.23, p Z 0.03), and short duration of hypertension (OR
1.12, p < 0.01) as independent predictors of a post-
operative decrease of 75% or greater in the DDD (Table 4).of 75% or greater in the defined daily dose.
Variable Odds ratio p
(95% CI)
No medical history of
cardiovascular disease
5.44 (1.27e23.28) 0.02
Low BMI 1.23 (1.02e1.47) 0.03
Short duration of hypertension 1.12 (1.04e1.22) <0.01
BMI Z body mass index; CI Z confidence interval.4. Discussion
This study is the first to use the DDD as the unit of mea-
surement to assess postoperative changes in antihyper-
tensive drug consumption in PA patients. The DDD is
suitable for therapeutic analyses and at the individual
level.12e18 The DDD has been used to measure antihyper-
tensive drug utilization in individual patients and to assess
the effects of invasive treatment for renal artery stenosis.17
The DDD can assess postoperative changes in antihyper-
tensive drug consumption, even though the antihyperten-
sive drug classes changed after treatment.12,17
Despite a decreased DDD in most patients, nine patients
could not postoperatively reduce their antihypertensiveTable 3 Univariate analyses of candidate predictors for a
postoperative decrease of 75% or greater in the defined
daily dose.
Variable 75% decrease <75% decrease p
(N Z 58) (N Z 52)
Age (y) 48  13 55  10 <0.01
Sex (female) 66 44 0.04
BMI (kg/m2) 22  2.7 24  3.4 <0.01
Family history of
hypertension, %
50 48 0.99
Comorbidities
Cardiovascular
disease
9 29 0.01
Diabetes mellitus 10 19 0.29
Subclinical
Cushing
syndrome
12 21 0.30
Duration of
hypertension (y)
(0e30) (1e35) <0.01
Preop DDD of
antihypertensive
drugs
2.1  1.1 2.8  1.1 <0.01
Preop systolic
BP (mmHg)
147  22 158  22 <0.01
Preop diastolic
BP (mmHg)
87  14 94  14 0.24
Preop clinical laboratory values
Serum potassium
(mmol/L)
2.9  0.5 3.0  0.6 0.33
PAC (ng/dL) 31.8 (2.3e92.1) 29.9 (3.0e160.0) 0.95
PRA (ng/mL/h) 0.1 (0.0e1.2) 0.2 (0.0e4.1) 0.04
eGFR (mL/min/
1.73 m2)
76.3  19.2 63.0  17.3 <0.01
Data are presented as mean  SD or median (range), unless
otherwise indicated.
BMI Z body mass index; BP Z blood pressure; DDD Z defined
daily dose; eGFR Z estimated glomerular filtration rate;
PAC Z plasma aldosterone concentration; PRA Z plasma renin
activity; Preop Z preoperative.drug use to control their BP. Based on the number of anti-
hypertensive drug classes, some patients were post-
operatively categorized into the hypertension improvement
group (i.e., they had a lower BP and took a fewer number of
antihypertensive drug classes). This was first revealed by
using the DDD because it can reflect the total consumption
of antihypertensive drugs. Assessing postoperative changes
in antihypertensive drug consumption by the number of
antihypertensive drug classes alone may mislead clinicians.
Multivariate analysis identified no medical history of
cardiovascular disease, low BMI, and short duration of hy-
pertension as independent predictors of a postoperative
decrease in the DDD of 75% or more (Table 4). Cardiovas-
cular disease was a robust predictor for decreased antihy-
pertensive drug consumption in the present study, although
it was not significantly associated with hypertension cure in
our previous study.21 The total consumption of antihyper-
tensive drugs depends on patient-related factors such as
the severity of the disease. Thus, in patients with a medical
history of cardiovascular disease, antihypertensive drug
consumption was not markedly decreased after surgery.
Clinicians would hesitate to decrease antihypertensive
drugs to control BP postoperatively because of the medical
history of cardiovascular disease.
The excessive production of aldosterone in PA patients
leads to a higher frequency of cardiovascular events,
compared to essential hypertension patients.8 In view of
the postoperative decrease of antihypertensive drug con-
sumption and prevention of cardiovascular disease, early
diagnosis and treatment of PA are the most important tasks
to maximize the benefits of laparoscopic adrenalectomy
and to minimize the progression of hypertension-mediated
vascular damage.21,22
The present study had some limitations. First, the
retrospective nature of this study may have affected the
quality of the data. This study included patients over a long
period (between 1995 and 2012), and the initial diagnostic
criteria for PA varied because of the lack of a generally
accepted diagnostic algorithm for PA throughout this
period. However, each patient was uniformly reviewed
before being included in the study. Second, some drugs
such as benidipine have not been assigned DDDs. Thus, it
was not possible to assess antihypertensive drug consump-
tion in patients taking the drugs that have not been
assigned DDDs. Third, the assigned DDD is based on the
recommended dose with reference to a 70-kg person. The
assigned DDDs may be slightly higher for Japanese people
because a Japanese person’s weight is generally lower than
194 T. Utsumi et al.a Western person’s weight. However, using DDD as a unit of
measurement is not an issue when comparing drug con-
sumption in one person.
In many PA patients, laparoscopic adrenalectomy could
inducea significant fall inantihypertensivedrugconsumption.
However, the total consumption of antihypertensive drugs
may not be decreased as much in PA patients with a medical
history of cardiovascular disease. Furthermore, even though
the preoperative number of antihypertensive drug classes
decreased, attention should be paid to the total consumption
ofantihypertensivedrugs tocontrolBPinPApatients. TheDDD
is a useful tool for assessing the total change in the con-
sumption of antihypertensive drugs in PA patients. Clinicians
could use the DDD to explain in detail to PA patients the
postoperative change in antihypertensive drug consumption.
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